[{"id":"bc4afe61-ff46-400f-b517-e50e3b2d936a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03633110","created_at":"2021-01-18T17:50:34.281Z","updated_at":"2024-07-02T16:36:12.103Z","phase":"Phase 1/2","brief_title":"Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine","source_id_and_acronym":"NCT03633110","lead_sponsor":"Genocea Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • GEN-009"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/08/2021","primary_completion_date":" 12/08/2021","study_txt":" Completion: 02/28/2022","study_completion_date":" 02/28/2022","last_update_posted":"2022-04-19"}]